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Small molecules that can alter stem cell fate are of immense biological and therapeutic values. In this
issue ofChemistry & Biology, Saxe and colleagues [1] report a chemical genetic screen that identified
an orphan ligand, P-Ser, which can modulate neural stem/progenitor cell fate.Neural stem cells (NSCs) are multipo-
tent cells that have the capacity to
self-renew and have the potential to
give rise to all the three fundamental
cell lineages of the central nervous
system. Unlike many other tissue
stem cells, NSCs differ in their multi-
potency and lineage commitment de-
pending on the developmental stage
of the organism as well as the region
of the brain from which they are iso-
lated [2]. However, considering the
ethical and political debates surround-
ing the use of human embryonic stem
cells, NSCs offer a noncontroversial
alternative to developing stem-cell-
based therapies for many incurable
neurodegenerative diseases as well
as in exploring novel therapies for
brain cancer. Moreover, the recent
finding that multipotent stem/progeni-
tor cells exist at least in three distinct
regions of the adult mammalian brain,
where neurogenesis persists through
adulthood [3], has elicited a genuine
possibility of noninvasive endogenous
brain repair as a viable alternative for
cell transplantation therapy. However
to exploit the full therapeutic potential
of NSCs it is critical to have an in-depth
understanding of the molecular mech-
anisms underlying their self-renewal,
differentiation, migration, and survival.
Additionally, reagents and methods
need to be generated that could pro-
vide a continuous supply of these cells
and manipulate their cell fate choice.
Neural stem/progenitor cells can be
isolated from embryonic, fetal, or adult
brain tissues and after dissociation
they can be expanded in vitro as
monolayer or as floating spheres of
cells in the presence of growth factors
such as bFGF and/or EGF. Such neu-
rospheres contain a heterogeneous974 Chemistry & Biology 14, September 2mix of stem cells, progenitors, and
differentiated cells. Growth factor
responsive stem/progenitor cells from
such a mixture can be serially pas-
saged to form new spheres and can
be expanded over at least several pas-
sages [4]. However, their proliferative
and multipotent nature drastically de-
clines over several passages. Upon
growth factor withdrawal NSCs spon-
taneously differentiate, to a lesser ex-
tent to neurons andmostly to astroglia.
Though having its own technical short-
comings, neurosphere assay is still
one of the most widely used tech-
niques for isolating and validating neu-
ral stem cells from embryonic and
adult CNS.
Candidate gene approaches and
knockout animal models have pro-
duced vital information regarding the
biology of NSCs. However, such stud-
ies so far are restrictedmostly to highly
studied pathways such as Wnt,
Shh, and Notch, etc. Considering the
wealth of genetic information available
to us in the postgenomic era, and the
complexity of gene and protein inter-
action networks that operate in con-
cert with cell extrinsic cues to produce
a given phenotype, such gene-centric
approaches could yield only limited
information in a given period of time.
Cell-based high-throughput pheno-
typic screens using cDNA and RNAi
arrays have recently emerged as a
technique for whole genome level
studies. Synthetic small molecule li-
braries offer a simple cost-effective,
yet highly valuable, alternative to this
approach [5].
Historically, small molecules have
contributed immensely to the progress
in biological science. Small molecules
have been identified that are capable007 ª2007 Elsevier Ltd All rights reservedof modulating specific stem cell fate
(e.g., all-trans retinoic acid, ESCs,
NSCs, MSCs) and some have found
several clinical applications (e.g.,Glee-
vac-imatinin mesylate; cancer stem
cells in leukemia). Since there are end-
less possibilities of generating struc-
turally diverse small molecules, this
approach has been used to target an
increasing number of proteins. Using
advanced automation combined with
chemiluminescence/fluorescence mi-
croscopy or image-based detection
for end-point read out (appropriate
marker staining or reporter gene activ-
ity and/or cell morphology), millions of
small molecules can be screened for
a phenotype in a short period of time.
Though extremely powerful there
are only few studies reported to date
that have employed the aforemen-
tioned strategy to study NSCs or
stem cells in general. Using the above
approach, we reported a novel small
molecule (from a combinatorial library
of 50,000 compounds), neuropathia-
zol, which selectively induced robust
differentiation of multipotent hippo-
campal neural progenitors to neurons
[6]. More recently Diamandis and col-
leagues, using a similar strategy,
screened a library of 1267 pharmaco-
logically active compounds for inhibi-
tors of neurosphere proliferation [7].
The screen results revealed a complex
interplay of signaling pathways that
govern the proliferation and self-rene-
wal of NSCs. Interestingly many of
these compounds, which are modula-
tors of adult neurotransmission path-
ways, have antiproliferative effects on
brain cancer stem cells, too.
In this issue of Chemistry & Biology,
Saxe et al. [1] describe an elegant
study that reports the identification of
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differentiation of mammalian NSCs, by
screening hundreds of bioactive com-
pounds. Following up on one of those
enhancers, the orphan ligand phos-
phoserine (P-Ser), the authors demon-
strate a novel link between the group III
metabotropic glutamate receptor 4
(mGluR4; yet another neurotransmis-
sion component) and neurogenesis.
In the initial screen using neuro-
spheres generated from embryonic
day 11.5 (E11.5) brain the authors
identified 64 hits (a surprisingly high
number considering the total number
of compounds screened) from which
fourteen were selected for secondary
assays. Five compounds from that
group were confirmed to modulate
neuronaldifferentiation (four enhancers
and one inhibitor). Clonal analysis and
RT-PCR for neurogenic transcription
factors revealed that P-Ser treated cul-
tures were twice as neurogenic as the
control. Furthermore, time course ex-
periment and TUNEL assay of E14.5
neuronal cultures suggested a neuro-
protective effect of this compound.
Target identification and elucidation
of the mechanism of action is often the
most challenging aspect of chemical
genetic screens. However, in the exist-
ing literature there are indirect evi-
dences that connect P-Ser to neuro-
genesis. In the brain P-Ser acts as
the substrate for phosphoserine phos-
phatase (PSP) that converts it to L-
serine, an essential amino acid that
has a critical role in cellular prolifera-
tion, cell–cell communication, and as
a glial-derived trophic factor. Recently,
PSP was identified to be specifically
expressed by the neural progenitors
and stem cells within the neurogenic
region in adult and embryonic brain
[8]. Additionally, PSP knockdown
could inhibit proliferation of the neuralCprogenitors, indirectly suggesting that
unmetabolized P-Ser may contribute
to this phenotype.
Interestingly, it is observed that
P-Ser can specifically bind to the glu-
tamate receptor mGluR4 with very
high affinity [9]. Enhancers of mGluR4
are also reported to have an inhibitory
effect on the proliferation and pro-
mote the differentiation in cerebellar
granule cell neural precursors [10].
However a direct role of this receptor
in neuronal differentiation of NSCs is
not established. The authors hence
tested the involvement of mGluR4 in
the observed phenotype. To their de-
light, inhibition of mGluR4 by siRNA or
through its specific antagonist abro-
gated the neurogenic and antiprolif-
erative activity of P-Ser, thus strongly
suggesting that its observed activity is
mediated through mGluR4.
Group III metabotropic receptors
function by reducing the cAMP levels
through inhibition of Gs activated ad-
enylyl cyclase [8]. However forskolin,
an adenylyl cyclase activator, has
been found to induce neurogenesis in
P19 embryonal carcinoma cells, ES-
cell-derived neuroepithelial cells, and
rodent neural stem cells [5]. Thus it is
intriguing that the inhibitor of such ac-
tivity can also elicit the similar pheno-
type in NSCs. It is possible that neu-
rogenic activity of mGluR4 may be
independent of its action on cAMP
levels or this activity may be restricted
to stage-specific subsets of progeni-
tors. Considering themosaic organiza-
tion of NSCs in adult mammalian brain
[2], it would be interesting to test
whether P-Ser has similar neurogenic
activity in diverse population of NSCs.
Additionally, usefulness of P-Ser in
inhibiting the proliferation of cancer
stem cells could also be explored.
Pharmacological testing of P-Ser andhemistry & Biology 14, September 2007 ª2other mGluR4 agonists in appropriate
animal models would help determine
the therapeutic potential of those
compounds.
In summary, Saxe et al. [1] have
described a simple chemical genetic
screen to identify modulators of neu-
ronal differentiation of neural stem/
progenitor cells. The methodology can
be conceptually applied for the study
of other stem cells. Their research has
also opened up new avenues that can
be explored for therapeutic interven-
tions of neurodegenerative disorders
and studying thebiology of neural stem
cells.
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